Ticker

Shares of Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have assigned a buy recommendation to the

Data from the Phase 3 sunRIZE study remains under review by FDA  The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026…

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Bank of America Corp DE reduced its stake in Rezolute, Inc. (NASDAQ: RZLT) by 31.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,970,549 shares of the company's stock after selling 1,354,699 shares during the period. Bank of America Corp

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.